1477.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 11:08):

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China...

Stats
Dzisiejszy wolumen	834 000
Średni wolumen	646 706
Kapitalizacja rynkowa	4.82B
EPS	HKD0 ( 2023-08-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-11.17
ATR14	HKD0.0260 (0.36%)

Wolumen Korelacja

Długi: -0.12 (neutral)

Krótki: 0.38 (neutral)

Signal:(45.765) Neutral

Ocumension Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocumension Therapeutics Korelacja - Waluta/Towar

-0.64
( weak negative )

-0.08
( neutral )

0.00
( neutral )

-0.74
( moderate negative )

-0.19
( neutral )

-0.74
( moderate negative )

Ocumension Therapeutics Finanse

Annual	2023
Przychody:	HKD246.37M
Zysk brutto:	HKD144.37M (58.60 %)
EPS:	HKD-0.590

FY	2023
Przychody:	HKD246.37M
Zysk brutto:	HKD144.37M (58.60 %)
EPS:	HKD-0.590

FY	2022
Przychody:	HKD158.96M
Zysk brutto:	HKD102.92M (64.74 %)
EPS:	HKD-0.640

FY	2021
Przychody:	HKD56.15M
Zysk brutto:	HKD36.94M (65.78 %)
EPS:	HKD-0.452

Financial Reports:

No articles found.

Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.